Chuangying Medical Completes Nearly RMB 100 Million Series A Financing Led by Shenghe Capital and Mingfeng Capital

VCBeat has learned that Jiangsu Trausim MEDICAL Instrument Co., Ltd. (“Trausim Medical”) has recently completed an A-round financing of nearly RMB 100 million. The round was co-led by Shenghe Capital and MingFeng Capital, with participation from four other medical funds, including Changzhou Ruiqi. The proceeds will be used to expand production capacity for core products, develop new products, obtain product registrations, build the brand, and enhance the capabilities of the marketing and service team.

Trausim Medical, established in 2010, specializes in dental implant systems and surgical instruments as its core products.For many years, Trausim Medical has remained committed to its original aspiration and mission of “providing one-stop implant restoration solutions for implant dentists and patients,” continuously exploring advancements in products and technologies within the field of dental implant restoration.

In terms of medical device R&D, Trausim adheres to a strategy of intensive investment in research and development, establishing a comprehensive, independently developed core technology system. It continuously drives technological innovation and product development in response to market dynamics. To date, Trausim has secured 7 invention patents, 31 utility model patents, and 47 authorized patents.

Notably, Trausim Medical places significant emphasis on collaborating with domestic universities and specialized hospitals to jointly promote the translation of scientific research achievements in the field of dental implantology. In May 2022, as the lead institution, Trausim Medical, in collaboration with nine clinical medical units and higher education institutions, completed the five-year research and development of the National Ministry of Science and Technology’s “13th Five-Year” Key R&D Program project titled “Low-Modulus, High-Strength Hydrophilic Dental Implant System.” Through in-depth industry-academia-research cooperation with partner organizations, the Trausim team has further enhanced its technical capabilities and management standards.

Meanwhile, to solidify the foundation for brand success, Trausim Medical has deployed internationally top-tier production and testing equipment for dental implant systems at its Changzhou headquarters, completing further optimization and upgrading of the company’s production lines. Throughout the manufacturing process, comprehensive monitoring is implemented across all stages, including production and operations, establishing a management system aligned with international standards. This approach, combined with stable manufacturing processes and a robust global supply chain, provides multiple layers of assurance for product quality.

Regarding this financing round, Mr. Qian Xiaojin, Chairman and CEO of Trausim Medical, stated, “We extend our sincere gratitude to Shenghe Capital, MingFeng Capital, and other outstanding investment institutions for their support and confidence in Trausim’s current financing round. The successful completion of this round not only affirms the hard work and achievements of all Trausim employees as recognized by investors in the healthcare sector, but also demonstrates the industry’s confidence in the oral health field and Trausim Medical’s future development. The funds and resources secured from this financing will be utilized to further enhance Trausim’s production capacity, accelerate the R&D and market launch of new products, and enable our clinical and production teams to deepen their presence in frontline markets. This will allow us to provide safe and effective products to clinicians and patients with speed and precision, deliver professional technical services to primary healthcare institutions, and collaborate with other domestic brands to establish a trustworthy image for Chinese national brands.”

In the future, Trausim Medical will leverage its unique core competitive advantages in the dental industry to collaborate closely with strategic partners, continuously refining comprehensive solutions for dental implant restoration. By delivering high-quality services to implant dentists and edentulous patients, the company is committed to improving the oral health of the Chinese population and establishing itself as a trusted brand in China’s dental implant restoration sector.

Shenghe Capital was co-founded by seasoned professionals from renowned domestic and international private equity firms, investment banks, and leading industrial enterprises. It focuses on equity investments and industrial empowerment in the fields of intelligent manufacturing, new materials, healthcare, and carbon peaking and carbon neutrality. Shenghe Capital participated in the establishment and management of China’s first provincial-level railway and aviation industry fund, with a committed capital size of nearly RMB 30 billion. Committed to building long-term partnerships with high-growth enterprises and teams, Shenghe Capital upholds the philosophy of “endless growth (‘Sheng’) and collaborative harmony (‘He’),” driving industrial empowerment and win-win cooperation to jointly become a core force propelling the continuous advancement of China’s economy.

MingFeng Capital is a professional private equity fund management firm focused on the healthcare and wellness sector. Established in 2015, it is a qualified private fund manager registered with the Asset Management Association of China (AMAC). The company currently manages funds totaling nearly RMB 1 billion and has made investments and strategic layouts across multiple sub-sectors of healthcare and the medical aesthetics industry.

Since its registration and filing, MingFeng Capital has successively established offices in Chengdu and Beijing. Through years of dedicated cultivation, MingFeng Capital has invested in a number of high-quality enterprises, including Aier Medical (688050), Chengdu Badachu Medical Aesthetics Hospital, Rayone Genomics (688217), Junshintai, Lvzhu Biopharma, Tiluo Medical, Lanwei Medicine, Baihui Weikang, and Ruihua Kangyuan.